Randomized, Double‐Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid‐Induced Constipation in Patients with Chronic Noncancer Pain

Background Subcutaneous methylnaltrexone, a peripherally acting μ‐opioid receptor antagonist, improves opioid‐induced constipation (OIC) in patients with chronic noncancer pain. An oral methylnaltrexone formulation has been developed. Methods In this phase 3, double‐blind trial, adults with chronic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pain practice 2017-07, Vol.17 (6), p.820-828
Hauptverfasser:	Rauck, Richard, Slatkin, Neal E., Stambler, Nancy, Harper, Joseph R., Israel, Robert J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Analgesics, Opioid - adverse effects Analgesics, Opioid - therapeutic use Chronic Pain - drug therapy Chronic Pain - epidemiology Constipation - chemically induced Constipation - drug therapy Constipation - epidemiology Double-Blind Method Female Humans Injections, Subcutaneous Male methylnaltrexone Middle Aged Naltrexone - administration & dosage Naltrexone - analogs & derivatives Narcotic Antagonists - administration & dosage noncancer pain opioid‐induced constipation oral Quaternary Ammonium Compounds - administration & dosage Receptors, Opioid, mu - antagonists & inhibitors Relistor Treatment Outcome μ‐opioid receptor antagonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!